Article

What's the Best Part of National Cancer Survivors Day?

The community of patients and caregivers supports us through our cancer journey.

To celebrate National Cancer Survivors Day (June 7), I'm sharing a recent picture of me with Linnea Olson, a sister metastatic lung cancer patient and one of the bloggers (Outliving Lung Cancer) who inspired me to become a lung cancer blogger and advocate. She and I are both alive thanks to research and clinical trials. As Linnea phrased it on Twitter, "Medical research has our backs! Here's to fourteen more (and beyond) years!"

Janet and Linnea at HOPE Summit 2015

The community of lung cancer patients and caregivers, combined with family and friends, keeps me going despite the roller coaster of scans, progressions, side effects, and emotions that are an integral part of living with metastatic cancer. Mostly, I connect with them online. Meeting them in real life at conferences, fundraisers, advocacy meetings and social gatherings feels like coming home. We can talk for hours about matters great and small — whether it be the fear of progression or the perfect ice cream flavor.

Best wishes for a great day to my many patient friends in the lung cancer community — both on and off social media — and in other cancer communities as well. Here's to hoping all cancers will soon become either curable, or treatable as chronic illnesses.

It's also Chocolate Ice Cream Day. Coincidence? I think not!

[Image credit: LUNGevity (taken at the HOPE Summit May 1, 2015)]

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content